


April 6-7, 2016
Washington D.C. USA



Medical Bionics Summit²⁰¹⁶

Designing a New Generation
of Medical Devices to
Rehabilitate, Restore Function
and Cure Disease

Expert Speakers Include:



Dr. Douglas Weber
Program Manager
DARPA



Tim Denison
Technical Fellow
Neuromodulation
Medtronic



Larry Jasinski
CEO
ReWalk Robotics



Chad Bouton
Vice President, Advanced
Engineering
& Technology
**The Feinstein Institute
for Medical Research**



Magnús Oddsson
Director of R&D,
Prosthetics, Research
& Development
Össur



Tom Looby
President & CEO
Ekso Bionics

Exhibition Partners:



www.medicalbionics-summit.com

Tel: +1 212 537 5898 | Email: info@hansonwade.com [in](#) Medical Bionics

Researched & Developed By:



Welcome to Medical Bionics Summit 2016

A unique event dedicated to the design, development and commercialization of medical devices that adapt and augment the human body.

At a time when an increasing range of 'bionic' technologies are being deployed to restore the human body, the existing **medical, technical and regulatory challenges** continue to hamper the widespread adoption and use of these devices.

The Medical Bionics Summit 2016 is your opportunity to join an **interdisciplinary speaker faculty of academics, clinicians, scientists, engineers and business leaders**. This event is specifically designed to find collaborative solutions to shared challenges faced across the different technologies including **advanced prosthetics,**

wearable robotics, prosthetic organs, neural implants, bioelectronics and neuromodulation.

By **uniting the companies and institutions developing these technologies with the regulators, healthcare payers, patient advocates and the supply chain serving the industry**, this first of its kind summit will offer unrivalled networking, learning and benchmarking opportunities. Join this unique discussion of critical topics and the latest science impacting the design, development and commercialization of these breakthrough medical technologies.

Top 10 Reasons to Attend Medical Bionics Summit 2016

- 1** Discover **breakthroughs** in materials, components and manufacturing technologies
- 2** Find **solutions to critical engineering challenges**
- 3** Explore the **latest science in neurophysiology** to enhance neural interface technologies
- 4** Meet peers working across a wide range of related disciplines to **find new ways of tackling common challenges**
- 5** Learn from **successful case studies in neuromodulation**
- 6** Meet vendors with the capabilities to support your custom design and development requirements
- 7** Identify **new opportunities for collaboration** on emerging projects
- 8** Understand **what regulators and healthcare payers need** to see to support a market for your technology
- 9** Access **new sources of R&D funding** – from federal and private investment
- 10** Learn to **unlock the commercial potential** in developing bionic technologies

Speakers



Dr. Douglas Weber
Program Manager
DARPA



Magnús Oddsson
Director of R&D,
Prosthetics, Research &
Development
Össur



Chad Bouton
Vice President, Advanced
Engineering
& Technology
**The Feinstein Institute
for Medical Research**



Jay Martin
CP, LP, FAAOP
Martin Bionics



Bruce Simon
PhD, Vice President of
Research
Electrocore LLC



Tim Swift
Co-Founder
Otherlab Orthotics



Erik D. Engeberg
Ph.D. Assistant
Professor, Ocean
& Mechanical
Engineering
**Florida Atlantic
University**



Chuck Carignan
President & CEO
BionX Medical Technologies



Elizabeth Tyler-Kabara
MD, PhD, Associate
Professor of Neurological
Surgery & Bioengineering
University of Pittsburgh




Larry Jasinski
CEO
ReWalk Robotics




Peter Bloch
CEO
Bionik Laboratories Corp



Tim Denison
Technical Fellow
Neuromodulation
Medtronic



Karen Rommelfanger
PhD
Director, Neuroethics,
Assistant Professor,
Neurology
Emory University



Gene Civillico PhD
Neuroscientist, Center for
Devices & Radiological Health
FDA




Tracy Cameron PhD
VP of Clinical &
Regulatory Affairs
**Neurotechnology
Innovations Translator**



Stéphane Bédard,
President, CEO &
Chairman of the Board
B-TEMIAI



Tom Looby
President & CEO
Ekso Bionics



Sam Kesner, PhD
Principal Engineer
& Research Project
Manager
Myomo, Inc.

Conference Day One, April 6, 2016

9.00 Chair's Opening Remarks

Elizabeth Tyler-Kabara, MD, PhD, Associate Professor of Neurological Surgery & Bioengineering, **University of Pittsburgh**

Co-Chair:

Chad Bouton, Vice President, Advanced Engineering and Technology, **The Feinstein Institute for Medical Research**

The Developing Market for Medical Bionics

9.10 Update & Insight from DARPA – Advancing Research in Bionic Technologies

- New programs coordinated by DARPA – showcasing current projects
- Early results from active programs and implications for future research
- Collaboration opportunities - approaching and working with DARPA

Dr. Douglas Weber, Program Manager, **DARPA**

9.40 CDRH & Medical Device Innovation

Premarket review of innovative medical devices

- Presubmission process
- Early feasibility studies
- Clinical study designs

Regulatory science support of device innovation

- Biological model systems
- In silico model systems
- The science of patient input
- Medical Device Innovation Consortium

Gene Civillico PhD, Neuroscientist, Center for Devices & Radiological Health, **FDA**

Michael Hoffmann, Division of Neurological and Physical Medicine Devices, Center for Devices & Radiological Health, **FDA**

10.10 Panel Session: What do Stakeholders Need to be Doing to Move Bionic Technologies into the Mainstream?

- Establishing better clinical data to demonstrate the benefits of bionics
- Working with regulators to secure approvals
- Educating payers and making the case for coverage
- Identifying opportunities for collaboration to solve common challenges – in science, regulation, payer acceptance and engineering of devices
- Does the growth of the neuromodulation market offer a model for the development and adoption of other technologies?

Dr. Douglas Weber, Program Manager, **DARPA**

Larry Jasinski, CEO, **ReWalk Robotics**

Chuck Carignan, President & CEO, **BionX Medical Technologies**

Peter Bloch, CEO, **Bionik Laboratories Corp.**

11.00 Refreshments & Speed Networking

Design, Materials, Manufacture

12.00 Rethinking Exoskeletons – Using High Strength Fabrics & Air to Revolutionize Exoskeleton Design

- Using High Strength Fabrics to develop high specific power exoskeleton infrastructure
- Achieving significant cost and weight savings over conventional techniques
- Enabling performance benefits not demonstrated by existing devices

Tim Swift, Co-Founder, **Otherlab Orthotics**

12.30 Case Study: NASA Robotics Research Advances Modular Prosthetic Interface Designs

- Re-designing the man/machine interface – advantages of fabric vs. rigid sockets
- The path from NASA and DoD exoskeleton research to transformational prosthetics
- Implications for the next generation of prosthetics

Jay Martin, CP, LP, FAAOP,
Martin Bionics

13.00 Using EMG-controlled Orthotics to Restore Volitional Control & Functional Ability to Paralyzed Upper Limbs.

- Using myoelectric control of orthotics return volitional movement to people with paralysis
- Myomo proprietary technology – enabling the use of weakened or impaired EMG signals to control a powered device
- Presenting examples of how we use a range of EMG signals to enable movement
- How we solved the challenges of adding multiple DOF of EMG control to our device, allowing a paralyzed arm to both reach and grasp
- Case studies: How this tech has helped patients restore function in their impaired arms, live independently and safely at home, and return to work

Sam Kesner, PhD, Principal Engineer & Research Project Manager, **Myomo, Inc.**

13.30 Networking Lunch

14.30 Case Study: Additional Dexterity with an Artificial Hand Provides Functional Improvements in Activities of Daily Life for Upper-Limb-Absent People

- Comparing performance of a dextrous (research) artificial hand with commercially available prosthetics
- Evaluating the impact of additional actuated joints for patients' task performance and perception of difficulty
- Results and the implications for the improvement of commercially available prosthetics

Erik D. Engeberg, Ph.D. Assistant Professor, Ocean & Mechanical Engineering, **Florida Atlantic University**

15.00 Miniaturization Challenges in Bionic Devices

- Minimizing weight when every gram counts
- The market for miniaturized motors, batteries and components – are vendors able to supply your demand?
- Overcoming power and signalling challenges for miniaturised devices
- Designing for energy efficiency

Chuck Carignan, President & CEO, **BionX Medical Technologies**

15.30 Refreshments & Networking

The Ethics of Developing & Deploying Bionic Technologies

16.00 Examining the Ethical Landscape of Bionic Technologies

- Cognitive Enhancement and Augmentation: What should the aspirations and limits be to interventions?
- Cybersecurity and Big Data Collection: How do we protect neural privacy?
- Prosthetics and Personal Identity: Can technologies change who you are?
- Safety: What are the physical and nonphysical benefits and harms of short and long-term use of these technologies?
- Beyond the clinical research: Can we serve as responsible stewards of these technologies as they inevitably move into legal and national security domains or even direct-to-consumer and DIY domains?

Session Leader
Karen Rommelfanger PhD, Director, Neuroethics, Assistant Professor, Neurology, **Emory University**

17.30 Chair's Closing Remarks

Conference Day Two, April 7, 2016

8.50 Chair's Opening Remarks

Elizabeth Tyler-Kabara, MD, PhD, Associate Professor of Neurological Surgery & Bioengineering, **University of Pittsburgh**

Co-Chair:
Chad Bouton, Vice President, Advanced Engineering & Technology, **The Feinstein Institute for Medical Research**

Human / Machine Interfaces

9.10 Panel Session: Evaluating Advances Human / Machine & Human / Computer Interfaces

- Invasive vs. non invasive technologies
- Breakthroughs in reading neural signals
- Determining the optimal interface for each application
- Designing control systems for prosthetics and implants
 - Balancing safety, autonomy and patient control
 - Interpreting and incorporating device feedback

Magnús Oddsson, Director of R&D, Prosthetics, Research & Development, **Össur**

Chad Bouton, Vice President, Advanced Engineering & Technology, **The Feinstein Institute for Medical Research**

Tim Denison, Technical Fellow, Neuromodulation, **Medtronic**

Tom Looby, President & CEO, **Ekso Bionics**

10.30 Refreshments & Networking

11.00 Case Study: Implanted Electrodes as Proportional Control for Lower Limb Prosthetics

- Using implanted electrodes as the primary means of capturing user intent when making control decisions for lower limb bionic devices
- Presenting early results from on-going experiments with this method
- How patient control and artificial intelligence control can co-exist without interference

Magnús Oddsson, Director of R&D, Prosthetics, Research & Development, **Össur**

Neuromodulation - the Electroceutical Future

11.30 Cracking the Neural Code & the Future of Bioelectronic Medicine

- Decoding brain signals to restore movement in paralyzed patients
- Adapting neural decoding to the field of Bioelectronic Medicine for treating a wide variety of diseases and conditions - without drugs

Chad Bouton, Vice President, Advanced Engineering & Technology, **The Feinstein Institute for Medical Research**

12.00 Exploring the Translation of Bi-Directional Brain-Machine Interfacing Technology

- Summary of the state-of-the-art and needs
- Future technology concepts motivated by need to better treat neurological conditions
- First: using BMI to research and better understand neural dynamics and modulation concepts
- Second: future, potentially apply this learning to better therapies, from modulation to prosthesis?
- Discussion of the remaining hurdles and possible next steps

Tim Denison, Technical Fellow, Neuromodulation, **Medtronic**

12.30 Networking Lunch

13.30 Getting Neuromodulation Devices to Market: Clinical & Regulatory Considerations

- Insights into successful trial design and execution
- Achieving product approval through direct negotiation with regulatory bodies
- Understanding and navigating clinical and regulatory concerns specific to neuromodulation

Tracy Cameron, PhD, VP of Clinical & Regulatory Affairs, **NIT**

14.00 **The Future of BCI: From Current State of the Art to Clinical Tools**

- Best of EEG, ECoG and Microarray Technology
- Best Interfaces to Assistive Technology
- Technical challenges
- Regulatory challenges
- Payor challenges
- Strategies for Success

Elizabeth Tyler-Kabara, MD, PhD, Associate Professor of Neurological Surgery & Bioengineering, **University of Pittsburgh**

14.30 **Non-Invasive Vagus Nerve Stimulation in the Treatment of Primary Headache: Mechanism of Action & Clinical Results**

- Evidence that nVNS can stimulate action potentials in the cervical vagus nerve
- What we have learned from nVNS in animal models of headache, stroke and bronchoconstriction
- Initial clinical results in asthma, migraine and cluster headache with nVNS
- Future potential application of nVNS in central and peripheral disorders

Bruce Simon, PhD, Vice President of Research, **Electrocore LLC**

15.00 **Refreshments & Networking**

Designing the Future: Towards Widespread Adoption of Bionic Technologies & Therapies

15.30 **Panel Session: Designing a Future for the Industry – Medical Bionics in 2026**

- What key challenges remain to be overcome?
- How can the wider industry collaborate to address these?
- A roadmap from the lab to the clinic... and beyond
- The non-medical potential for bionic technologies

Stéphane Bédard, President, CEO & Chairman of the Board, **B-TEMIA**

Magnús Oddsson, Director of R&D, Prosthetics, Research & Development, **Össur**

Chad Bouton, Vice President, Advanced Engineering & Technology, **The Feinstein Institute for Medical Research**

16.15 **Chair's Closing Remarks**

■ ■ The difference between this event and others is that this allows us to exchange ideas with those with whom we share many common challenges. ■ ■

Abbvie, Past Attendee, Hanson Wade Event



■ ■ An excellent forum. I liked the fact that it was an intimate and engaging experience. ■ ■

Toronto Central Community Care Access Centre,
Past Attendee, Hanson Wade Event

Partnership Opportunities

Exhibition Partners



EOS

EOS is the world's leading technology and quality leader for high-end solutions in the area of additive manufacturing (AM). The company, which was founded in 1989, is a pioneer and global leader in the area of direct metal laser sintering, and also a provider of a leading polymer technology. For these industrial 3D printing processes, EOS offers a modular solutions portfolio that consists of systems, software, materials, as well as technical and AM consulting services

EOS Medical

Additive Manufacturing for Medical Devices

EOS' industrial 3D printing technology allows to produce specialised surgical instruments and medical devices quickly and cost-effectively.

Every person is unique. Therefore, optimal patient care in dentistry, orthopaedics and implantology requires medical products that provide a perfect fit. There is a high demand for one-off components and components produced in small production runs whose materials and manufacturing standards have to fulfil extremely stringent quality requirements.

www.eos.info/en
www.3dmicroprint.com

Become a Commercial Partner

Delegates attend this summit actively seeking outside expertise, collaborators and partners to help them with a range of challenges.

Attendees are actively seeking solutions in:

- 3D printing / additive manufacturing
- Contract Manufacturing
- Design and control software
- Batteries and power
- Motors
- Components
- Microprocessors
- Materials / biomaterials

If you have a product or service that would help this audience, Medical Bionics Summit 2016 is the perfect opportunity to showcase it. By sponsoring or exhibiting you **get access to your market** at a time when they are engaged in evaluating solutions and selecting partners.

Network, make contacts, demonstrate your technology and establish your credibility in the market. We can tailor a sponsorship option that meets your commercial needs. Contact us to discuss your requirements.

Contact

Mo Langhi
Commercial Manager

Tel: +1 212 537 5898
Email:
sponsor@hansonwade.com



Media Partner



The International Neuromodulation Society (INS)

The International Neuromodulation Society (INS) is a non-profit group of clinicians, scientists and engineers dedicated to the scientific development and awareness of neuromodulation - the alteration of nerve activity through the delivery of electrical stimulation or chemical agents to targeted sites of the body. Founded in 1989, INS educates and promotes the field through its conferences, MEDLINE-indexed journal, Neuromodulation: Technology at the Neural Interface, and website. INS has over 2,100 members and 20 regional chapters.

www.neuromodulation.com

*The INS and the Medical Bionics Summit both strive for improved technology to improve patient lives. The INS has not endorsed the Medical Bionics Summit, but applauds the efforts of the summit to advance the field.

Venue & Pricing

Venue

Sheraton Pentagon City Hotel

900 South Orme Street
Arlington,
Virginia
22204
United States

Tel: +1 703 521 1900

Accommodation: Overnight accommodation is not included in the registration fee.



Register

www.medicalbionics-summit.com/register

Tel: +1 212 537 5898

Email: register@hansonwade.com

Mail:

Hanson Wade
4th Floor, 52 Grosvenor Gardens,
London, SW1W 0AU

Team Discounts*

- **10% discount** – 3 delegates
- **15% discount** – 4 delegates
- **20% discount** – 5 or more delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Event Prices

	Standard Prices
Academics	\$900
Medical Device Companies	\$1,500
Vendors	\$3,000



Terms & Conditions

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organisation can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, 4th Floor, 52 Grosvenor Gardens, London, SW1W 0AU

Hanson Wade Limited. Registered in England & Wales. Company No: 6752216

* All discount offers (including team discounts) require payment at the time of registration to receive any discount. 'Early Bird' discounts require payment at time of registration and on or before the cut-off date to receive any discount. All discount offers cannot be combined with any other offer. The conference fee includes lunch, refreshments and course documentation. The fee does not include travel or hotel accommodation.